O'Gorman, P., Laubach, J., Clifford, R., Mo, C., Kumar, S., Nadeem, O., Hartley-Brown, M., Glavey, S., Midha, S., Liu, Y., Vase, M., Pratz, K., Hayden, P., Liegel, J., Dowling, P., Benjamin, E., Donachie, V., Beers, Z., McLoughlin, O., Horwitz, L., Marron, J., Sueiro, E., Nolan, M., Poretsky, D., Shevlin, A., Beaton, S., Prior, C., Piper, C., Krishnanivas, B., Simpson, E., Karimi, E., Davis, M., McAlester, L., Allen, A., Richardson, P. (2025). Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI). Blood. https://doi.org/10.1182/blood-2025-4030